Treatment of non–small-cell lung cancer (NSCLC) has shifted away from one-size-fits-all chemotherapy to the evolving use of precision medicine based on histology, biomarkers, and specific patient factors. This eCase details evidence for the individualization of first-line therapy in patients whose tumors lack an actionable biomarker, with a discussion of appropriate biomarker testing, current and emerging therapeutic options, and the selection of maintenance therapy.
Case study with interactive benchmarking
To promote the individualization of treatment for patients with advanced NSCLC without an actionable biomarker, based on histology, biomarker testing, evidence for current and emerging treatment options, and maintenance therapy.
After completing this activity, participants should be better able to:
- Discuss current clinical trial data regarding individualization of therapy for patients with NSCLC based on histology and biomarkers
- Identify options for first-line treatment for patients with NSCLC lacking an activating mutation
- Incorporate maintenance therapy in an evidence-based manner for patients with stable or responding disease after upfront therapy
- Apply strategies to prevent and manage adverse events associated with systemic therapy used in the treatment of squamous and nonsquamous cell lung cancer
Oncology nurse practitioners, physician assistants, and nurses
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing contact hours: 0.50, which includes 0.25 hours of pharmacology credit
This program has been reviewed and is approved for a maximum of 0.50 AAPA Category 1 CME credits by the AAPA Review Panel. Approval is valid for one year from the issue date of May 5, 2017. Participants may submit the post-test at any time during that period.
This program was planned in accordance with AAPA CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
This activity was supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, the AAPA, or Lilly.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are expected to disclose to the audience any significant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Ms Eaby-Sandy: speaker: Amgen, Helsinn, Merck; advisory board: Ariad.
The Planning Committee for this activity included Ruth Cohen and Devera Pine of Continuing Education Alliance; and Jessica Garner, MMS, PA-C, of the University of the Pacific. The members of the Planning Committee have no significant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Read the eCase in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 66%.
The estimated time to complete this activity is 0.50 hours.
Release date: May 5, 2017
Expiration date: May 5, 2018
© 2018 Practicing Clinicians Exchange. All Rights Reserved. LPCE92017